Product News from the 02/03 News Brief

Share this article:
The FDA has approved Sucampo Pharmaceuticals’ Amitiza (lubiprostone) capsules, an oral treatment of chronic idiopathic constipation in adults. Amitiza is the first selective chloride channel activator approved for therapeutic use and has been found effective in the relief of chronic idiopathic constipation in adults. CV Therapeutics’ Ranexa (ranolazine extended-release tablets) won FDA approval for the treatment of chronic angina. The FDA has approved Cangene’s HepaGam B (hepatitis B immune globulin, human) for treatment following acute exposure to the hepatitis B virus. The FDA granted ISTA Pharmaceuticals’ Xibrom (bromfenac ophthalmic solution) the expanded indication of treatment of pain following cataract surgery.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.